Non-agonist PPARG Modulators for Osteoporosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for progressive bone diseases, such as osteoporosis and Paget's Disease, using PPARG agonists like glitazones, often lead to side effects like weight gain, edema, and cardiac hypertrophy due to agonism of the PPARG receptor, which can impair bone health and metabolism.
Innovation Solution
Development of non-activating PPARG modulators, specifically compounds of formulas (I) and (IA), that inhibit kinase-mediated phosphorylation of PPARG without activating the receptor, thereby reducing side effects and promoting bone health by inhibiting bone resorption and improving bone formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PPARG agonists (glitazones) are used to treat progressive bone diseases, then bone resorption is inhibited and bone formation is improved, but side effects occur including weight gain, edema, cardiac hypertrophy, and impairment of bone growth or formation
Solution Approach 1:
The patent segments the pharmacological action into two distinct components: kinase inhibition (to prevent PPARG phosphorylation and activation) and bone protective effects (to achieve therapeutic benefit). By targeting the upstream kinase rather than the PPARG receptor itself, the treatment achieves bone protection without triggering the harmful downstream effects of PPARG agonism such as weight gain, edema, and cardiac hypertrophy.
Solution Approach 2:
The patent introduces an intermediary mechanism by blocking kinase-mediated phosphorylation of PPARG. Instead of directly activating or inhibiting PPARG, the compounds prevent its activation through phosphorylation, serving as an intermediary that controls PPARG activity indirectly. This intermediary approach allows selective modulation of PPARG's role in bone metabolism while avoiding its harmful metabolic effects.
2Object-affected harmful factors
If kinase-mediated phosphorylation of PPARG is blocked to prevent receptor activation, then side effects are reduced, but treatment efficacy may be compromised
Solution Approach 1:
The patent changes the pharmacological parameter from direct receptor binding affinity to kinase inhibition capability. The compounds are designed to specifically inhibit the kinases that phosphorylate PPARG, altering the activation state of PPARG without directly interacting with the receptor. This parameter change enables selective control of PPARG's bone-protective functions while avoiding its harmful metabolic effects.
Data Source
AI summary
The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.